Demodicidosis
MONDO:0017280Demodicidosis is a rare parasitic cutaneous disease due to Demodex mite infestation characterized by variable degrees of spinulosis, erythema, papules, and pustules, usually accompanied by a burning or pruritic sensation. Face (incl. eyelids) is most frequently affected, but ear canal, scalp, neck, back, chest, nipples, buttocks, penis, and extremity (legs and arms) involvement have also been observed. Dermoscopic examination reveals Demodex tails and follicular openings.
Also known as: Demodex caused disease or disorder, Demodex disease or disorder, Demodex infectious disease, Demodicosis, demodectic mange, red mange
7 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Can light zap eyelid mites? new trial investigates
Disease control CompletedThis study tests two types of light therapy—low-level light and intense pulse light—to kill Demodex mites that cause eyelid inflammation (blepharitis). 88 adults with confirmed mite infections will receive one of four treatments: sham, blue light alone, IPL alone, or both. All wi…
Phase: NA • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Eyelid wipes zap Mite-Caused eye inflammation in new study
Disease control CompletedThis study tested whether cleaning the eyelids with wipes containing chlorhexidine can treat blepharitis caused by Demodex mites. 106 adults with the condition used the wipes twice daily for four weeks. Researchers measured mite counts and eyelash debris before and after treatmen…
Phase: PHASE4 • Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New eyedrop shows promise for Mite-Related dry eye
Disease control CompletedThis study tested an eyedrop called TP-03 in 39 people with meibomian gland dysfunction (a common cause of dry eye) linked to Demodex mites. The goal was to compare two dosing schedules (twice vs. three times daily) for safety and effectiveness. The results could lead to a new tr…
Phase: PHASE2 • Sponsor: Tarsus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC